Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells
Cancers are consequences of cellular dysfunction leading to an aberrant cellular multiplication and proliferation, subsequently yielding metastasis formation. Inflammatory reaction, with immune cell recruitment, is the main defense against precancerous lesions. However, an inflammatory environment a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.812171/full |
| _version_ | 1798021114757120000 |
|---|---|
| author | Audrey Wetzel Audrey Wetzel Francis Bonnefoy Francis Bonnefoy Cécile Chagué Mathieu Vetter Mélanie Couturier Blandine Baffert Olivier Adotévi Olivier Adotévi Philippe Saas Sylvain Perruche Sylvain Perruche |
| author_facet | Audrey Wetzel Audrey Wetzel Francis Bonnefoy Francis Bonnefoy Cécile Chagué Mathieu Vetter Mélanie Couturier Blandine Baffert Olivier Adotévi Olivier Adotévi Philippe Saas Sylvain Perruche Sylvain Perruche |
| author_sort | Audrey Wetzel |
| collection | DOAJ |
| description | Cancers are consequences of cellular dysfunction leading to an aberrant cellular multiplication and proliferation, subsequently yielding metastasis formation. Inflammatory reaction, with immune cell recruitment, is the main defense against precancerous lesions. However, an inflammatory environment also favors cancer cell progression, with cancer cell evasion from immune surveillance, leading to cancer development. Current therapeutic strategies enhance this natural immune response in order to restore immunosurveillance. The variety of these strategies is a predominant source of inflammatory mediators used by cancer cells to grow, differentiate, and migrate, therefore encouraging metastasis formation. For this reason, during cancer progression, limiting inflammation appears to be an innovative strategy to avoid the escape of cancer cells and potentially enhance the efficacy of antitumor therapies. Thus, this study aims to investigate the impact of administering pro-resolving factors (SuperMApo® drug candidate), which are inducers of inflammation resolution, in the framework of cancer treatment. We have observed that administering pro-resolving mediators issued from apoptotic cell efferocytosis by macrophages controlled peritoneal cancer progression by limiting cancer cell dissemination to the blood and mesenteric lymph nodes. This observation has been linked to an increase of macrophage mobilization in both peritoneal cavity and mesenteric lymph nodes. This control is associated to a restricted immunosuppressive myeloid cell circulation and to an IFN-γ-specific anti-tumor T-cell response. Altogether, these results suggest that administering proresolving factors could provide a new additional therapeutic alternative to control cancer progression. |
| first_indexed | 2024-04-11T17:08:48Z |
| format | Article |
| id | doaj.art-0fbbf3ab40294c698513f236f819d73b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T17:08:48Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0fbbf3ab40294c698513f236f819d73b2022-12-22T04:12:57ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-01-011210.3389/fimmu.2021.812171812171Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer CellsAudrey Wetzel0Audrey Wetzel1Francis Bonnefoy2Francis Bonnefoy3Cécile Chagué4Mathieu Vetter5Mélanie Couturier6Blandine Baffert7Olivier Adotévi8Olivier Adotévi9Philippe Saas10Sylvain Perruche11Sylvain Perruche12University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, FranceMED’INN’Pharma, Besançon, FranceUniversity of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, FranceMED’INN’Pharma, Besançon, FranceUniversity of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, FranceUniversity of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, FranceMED’INN’Pharma, Besançon, FranceUniversity of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, FranceUniversity of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, FranceDepartment of Medical Oncology, University Hospital of Besançon, Besançon, FranceUniversity of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, FranceUniversity of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, FranceMED’INN’Pharma, Besançon, FranceCancers are consequences of cellular dysfunction leading to an aberrant cellular multiplication and proliferation, subsequently yielding metastasis formation. Inflammatory reaction, with immune cell recruitment, is the main defense against precancerous lesions. However, an inflammatory environment also favors cancer cell progression, with cancer cell evasion from immune surveillance, leading to cancer development. Current therapeutic strategies enhance this natural immune response in order to restore immunosurveillance. The variety of these strategies is a predominant source of inflammatory mediators used by cancer cells to grow, differentiate, and migrate, therefore encouraging metastasis formation. For this reason, during cancer progression, limiting inflammation appears to be an innovative strategy to avoid the escape of cancer cells and potentially enhance the efficacy of antitumor therapies. Thus, this study aims to investigate the impact of administering pro-resolving factors (SuperMApo® drug candidate), which are inducers of inflammation resolution, in the framework of cancer treatment. We have observed that administering pro-resolving mediators issued from apoptotic cell efferocytosis by macrophages controlled peritoneal cancer progression by limiting cancer cell dissemination to the blood and mesenteric lymph nodes. This observation has been linked to an increase of macrophage mobilization in both peritoneal cavity and mesenteric lymph nodes. This control is associated to a restricted immunosuppressive myeloid cell circulation and to an IFN-γ-specific anti-tumor T-cell response. Altogether, these results suggest that administering proresolving factors could provide a new additional therapeutic alternative to control cancer progression.https://www.frontiersin.org/articles/10.3389/fimmu.2021.812171/fullcancerinflammationpro-resolving factorsanti-tumor responsemacrophages |
| spellingShingle | Audrey Wetzel Audrey Wetzel Francis Bonnefoy Francis Bonnefoy Cécile Chagué Mathieu Vetter Mélanie Couturier Blandine Baffert Olivier Adotévi Olivier Adotévi Philippe Saas Sylvain Perruche Sylvain Perruche Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells Frontiers in Immunology cancer inflammation pro-resolving factors anti-tumor response macrophages |
| title | Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells |
| title_full | Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells |
| title_fullStr | Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells |
| title_full_unstemmed | Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells |
| title_short | Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells |
| title_sort | pro resolving factor administration limits cancer progression by enhancing immune response against cancer cells |
| topic | cancer inflammation pro-resolving factors anti-tumor response macrophages |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.812171/full |
| work_keys_str_mv | AT audreywetzel proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT audreywetzel proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT francisbonnefoy proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT francisbonnefoy proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT cecilechague proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT mathieuvetter proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT melaniecouturier proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT blandinebaffert proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT olivieradotevi proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT olivieradotevi proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT philippesaas proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT sylvainperruche proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells AT sylvainperruche proresolvingfactoradministrationlimitscancerprogressionbyenhancingimmuneresponseagainstcancercells |